Company: SWKH
Filing Date: 2025-04-29
Form Type: ANNLRPT
Source: 0001628280-25-020720
Chunk: 46

Company: SWK Holdings Corp
Filing Date: 2025-04-29
Form: ANNLRPT
Chunk 46
---
 valuation allowance is recorded in the statement of operations in the period it is determined an adjustment is required.

Please refer to Note 14 of the notes to the consolidated financial statements in Part II, Item 8, Financial Statements and Supplementary Data .

#### Recent Accounting Pronouncements
For a discussion of recent accounting pronouncements, refer to Note 1 of the notes to the consolidated financial statements in Part II, Item 8, Financial Statements and Supplementary Data .

<div align='center'>26</div>

### Results of Operations
This section of this Annual Report generally discusses 2024 and 2023 items and year-to-year comparisons between 2024 and 2023. Discussion of 2023 items and year-to-year comparisons between 2023 and 2022 that are not included in this Annual Report can be found in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Part II, Item 7 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2023.

Comparison of the Years Ended December 31, 2024 and 2023

The following table summarizes the results of our operations:

| (in millions)                                                        |     | For the Year Ended 
 December 31,       | 2024 |     |   | 2023 |     | Change |      |
|:---------------------------------------------------------------------|:----|:-------------------|-----:|:----|:--|-----:|:----|:-------|-----:|
| Revenues                                                             |     | $                  | 45.0 |     | $ | 37.8 |     | $      |  7.2 |
| Provision for credit losses                                          |     |                    | 12.8 |     |   |  1.9 |     | $      | 10.9 |
| Loss on impairment of intangible assets                              |     |                    |  5.8 |     |   |    — |     | $      |  5.8 |
| Impairment of goodwill                                               |     |                    |    — |     |   |  8.4 |     | $      | -8.4 |
| Interest expense                                                     |     |                    |  4.7 |     |   |  1.8 |     | $      |  2.9 |
| Pharmaceutical manufacturing, research and development expense       |     |                    |  2.2 |     |   |